New stem cell combo aims to beat childhood cancers

NCT ID NCT02508038

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give the drug zoledronate after transplant to help the new cells grow. The main goal is to check safety, including risks like graft-versus-host disease or graft failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
stem cell transplant (from a half-matched donor) and zoledronate (a bone-strengthening drug)
What this could lead to
If it works, this could offer a new transplant option for children with cancers that have come back or not responded to treatment.
What could go wrong
This is a very early, small phase 1 trial focused on safety. It may not work for everyone, and there are risks like graft-versus-host disease or graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53705, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.